Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results Approval
Audit Opinion:
Unmodified review conclusion for both standalone and consolidated financial results
Key Financial Highlights [Amount in lakhs]:
Standalone Results:
Revenue from Operations: ₹12,702.91 lakhs (Q1 FY27) vs ₹7,800.70 lakhs (Q1 FY26) - 62.9% YoY growth
Total Income: ₹13,097.17 lakhs (Q1 FY27) vs ₹8,024.09 lakhs (Q1 FY26)
Net Profit: ₹189.72 lakhs (Q1 FY27) vs ₹590.44 lakhs (Q1 FY26) - 67.9% YoY decline
EPS: Basic ₹0.55 (Q1 FY27) vs ₹2.03 (Q1 FY26)
Other Equity: Not specified for current quarter
Cash and Cash Equivalents: Not specified
Debt: Not specified
Consolidated Results:
Revenue from Operations: ₹17,360.23 lakhs (Q1 FY27) vs ₹10,358.26 lakhs (Q1 FY26) - 67.6% YoY growth
Total Income: ₹17,564.57 lakhs (Q1 FY27) vs ₹10,445.87 lakhs (Q1 FY26)
Net Profit: Loss of ₹4,394.47 lakhs (Q1 FY27) vs Loss of ₹1,377.79 lakhs (Q1 FY26)
EPS: Basic ₹-12.58 (Q1 FY27) vs ₹-4.92 (Q1 FY26)
Profit attributable to owners of parent: Loss of ₹4,355.51 lakhs (Q1 FY27)
Non-controlling interest: Loss of ₹38.96 lakhs (Q1 FY27)
Other Equity: Not specified for current quarter
Cash and Cash Equivalents: Not specified
Debt: Not specified
Segment-wise Performance:
The Company has evaluated its operating segment in accordance with Ind AS 108 and has concluded that it is engaged in a single operating segment.
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital structure changes announced.
Other Significant Information:
Investments Made During Quarter:
i) ₹2,019.55 lakhs in Davaindia Health Mart Limited (Wholly Owned Subsidiary) by subscribing 39,794 equity shares at ₹5,075 per share (including premium of ₹5,065)
ii) ₹200.00 lakhs in Curexis Ventures Private Limited (Wholly Owned Subsidiary) by subscribing 1,000,000 equity shares at ₹20 per share (including premium of ₹10)
iii) ₹200.00 lakhs in KMHP Ventures Limited (Wholly Owned Subsidiary) by subscribing 2,000,000 equity shares at ₹10 per share
iv) ₹25.00 lakhs in Globotask IT Consultancy Services Private Limited by acquiring 8,000 equity shares at ₹312.50 per share (upon this acquisition, it became subsidiary of the Company)
Exceptional Items:
The Group has recognized an exceptional item of ₹599.98 lakhs due to the impact of new labour codes (effective November 21, 2025) which changed the definition of "wages" for employees, resulting in increased wage costs.
Lease Accounting:
The Group has adopted Ind AS 116 'Leases' and recognized Right-of-Use Asset of ₹21,872.57 lakhs and corresponding Lease Liability of ₹23,347.19 lakhs as at June 30, 2026. Impact on consolidated profit for Q1 FY27 is ₹177.86 lakhs.
Subsidiaries Included in Consolidation:
Wholly Owned Subsidiaries: Zota Healthcare Lanka (Pvt) Ltd, Davaindia Health Mart Limited, Zota Nex Tech Limited, Curexis Ventures Private Limited, KMHP Ventures Limited
Subsidiaries: Everyday Herbal Beauty Care Limited, Everyday Herbal Beauty and Wellness Care Private Limited, Globotask IT Consultancy Services Private Limited